Full Length Research Paper
References
Abdul-Aziz MH, Sulaiman H, Mat-Nor MB, Rai V, Wong KK, Hasan MS, Abd Rahman AN, Jamal JA, Wallis SC, Lipman J, Staatz CE, Roberts JA (2016). Beta-lactam infusion in severe sepsis (bliss): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis. Intensive Care Medicine 42(10):1535-1545. Crossref |
||||
Ariano RE, Nyhlén A, Donnelly JP, Sitar DS, Harding GK, Zelenitsky SA (2005). Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia. Annals of Pharmacotherapy 39(1):32-38. Crossref |
||||
Bader JC, Lakota EA, Dale GE, Sader HS, Rex JH, Ambrose PG, Bhavnani SM (2019). Pharmacokinetic-pharmacodynamic evaluation of ertapenem for patients with hospital-acquired or ventilator-associated bacterial pneumonia. Antimicrobial Agents and Chemotherapy 63(6):e00318-19. Crossref |
||||
Bergen PJ, Bulitta JB, Kirkpatrick CMJ, Rogers KE, McGregor MJ, Wallis SC, Paterson DL, Nation RL, Lipman J, Roberts JA, Landersdorfer CB (2017). Substantial impact of altered pharmacokinetics in critically ill patients on the antibacterial effects of meropenem evaluated via the dynamic hollow-fiber infection model. Antimicrobial Agents and Chemotherapy 61(5):e02642-16. Crossref |
||||
Brolund A (2014). Overview of ESBL-producing Enterobacteriaceae from a Nordic perspective. Infection Ecology and Epidemiology 4:24555. Crossref |
||||
Burkhardt O, Brunner M, Schmidt S, Grant M, Tang Y, Derendorf H (2006). Penetration of ertapenem into skeletal muscle and subcutaneous adipose tissue in healthy volunteers measured by in vivo microdialysis. Journal of Antimicrobial Chemotherapy 58(3):632-636. Crossref |
||||
Burkhardt O, Derendorf H, Welte T (2007). Ertapenem: the new carbapenem 5 years after first FDA licensing for clinical practice. Expert Opinion on Pharmacotherapy 8(2):8237-8256. Crossref |
||||
CDC (2019). Antibiotic Resistance Threats in the United States. U.S. Department of Health and Human Services, Atlanta: 2019. | ||||
Chai MG, Cotta MO, Abdul-Aziz MH, Roberts JA (2020). What are the current approaches to optimizing antimicrobial dosing in the intensive care unit? Pharmaceutics 12(7):638. Crossref |
||||
Clinical and Laboratory Standards Institute (CLSI) (2020). Performance standards for antimicrobial susceptibility testing: 30th ed. Document M100. Wayne, Pennsylvania: 2020. | ||||
Craig WA (1995). Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagnostic Microbiology and Infectious Disease 22(1-2):89-96. Crossref |
||||
Curran M, Simpson D, Perry C (2003). Ertapenem: a review of its use in the management of bacterial infections. Drugs 63(17):1855-1878. Crossref |
||||
Dailly E, Arnould JF, Fraissinet F, Naux E, Letard de la Bouralière MA, Bouquié R, Deslandes G, Jolliet P, Floch RL (2013). Pharmacokinetics of ertapenem in burns patients. International Journal of Antimicrobial Agents 42(1):48-52. Crossref |
||||
Doi Y (2020): Ertapenem, Imipenem, Meropenem, Doripenem, and Aztreonam. In: Bennett JE, Dolin R, Blaser MJ, editors. Mendell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 9th ed. Philadelphia, United States: Elsevier-Health Sciences Division, pp. 285-290.e2. | ||||
Doi Y, Iovleva A, Bonomo RA (2017). The ecology of extended-spectrum β-lactamases (ESBLs) in the developed world. Journal of Travel Medicine 24(suppl 1):S44-S51. Crossref |
||||
Drusano GL (2003). Prevention of resistance: a goal for dose selection for antimicrobial agents. Clinical Infectious Diseases 36(Suppl 1):S42-S50. Crossref |
||||
EUCAST (2020). MIC and inhibition zone diameter distributions of microorganisms without and with resistance mechanisms, |
||||
Gordien JB, Boselli E, Fleureau C, Allaouchiche B, Janvier G, Lalaude O, Saux MC, Breilh D (2006). Determination of free ertapenem in plasma and bronchoalveolar lavage by high-performance liquid chromatography with ultraviolet detection. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences 830(2):218-223. Crossref |
||||
Goutelle S, Valour F, Gagnieu MC, Laurent F, Chidiac C, Ferry C, Bone L, Joint Infection Study Group (2018). Population pharmacokinetics and probability of target attainment of ertapenem administered by subcutaneous or intravenous route in patients with bone and joint infection. Journal of Antimicrobial Chemotherapy 73(4):987-994. | ||||
Gutiérrez-Gutiérrez B, Rodríguez-Baño J (2019). Current options for the treatment of infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae in different groups of patients. Clinical Microbiology and Infection 25(8):932-942. Crossref |
||||
Heuberger J, Schmidt S, Derendorf H (2013). When is protein binding important? Journal of Pharmaceutical Sciences 102(9):3458-3467. Crossref |
||||
Lodise TP Jr, Lomaestro B, Drusano GL (2007). Piperacillin-tazobactam for pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clinical Infectious Diseases 44(3):357-363. Crossref |
||||
Majumdar AK, Musson DG, Birk KL, Kitchen CJ, Holland S, McCrea J, Mistry G, Hesney M, Xi L, Li SX, Haesen R, Blum RA, Lins RL, Greenberg H, Waldman S, Deutsch P, Rogers JD (2002). Pharmacokinetics of ertapenem in healthy young volunteers. Antimicrobial Agents and Chemotherapy 46(11):3506-3511. Crossref |
||||
Manyahi J, Kibwana U, Mgimba E, Majigo M (2020). Multi-drug resistant bacteria predict mortality in bloodstream infection in a tertiary setting in Tanzania. PLoS One 15(3):e0220424. Crossref |
||||
Masich AM, Heavner MS, Gonzales JP, Claeys KC (2018). Pharmacokinetic/pharmacodynamic considerations of beta-lactam antibiotics in adult critically ill patients. Current Infectious Disease Reports 20(5):9. Crossref |
||||
Onufrak NJ, Forrest A, Gonzalez D (2016). Pharmacokinetic and pharmacodynamic principles of anti-infective dosing. Clinical Therapeutics 38(9):1930-1947. Crossref |
||||
Pitout JDD, Laupland KB (2008). Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infectious Diseases 8(3):159-166. Crossref |
||||
Rodríguez-Baño J, Gutiérrez-Gutiérrez B, Machuca I, Pascual A (2018). Treatment of infections caused by extended-spectrum-beta-lactamase-, AmpC-, and carbapenemase-producing Enterobacteriaceae. Clinical Microbiology Reviews 31(2):e00079-17. Crossref |
||||
Santoro A, Franceschini E, Meschiari M, Menozzi M, Zona S, Venturelli C, Digaetano M, Rogati C, Guaraldi G, Paul G, Gyssens IC, Mussini C (2020). Epidemiology and risk factors associated with mortality in consecutive patients with bacterial bloodstream infection: impact of MDR and XDR bacteria. Open Forum Infectious Diseases 7(11):ofaa461. Crossref |
||||
Serra-Burriel M, Keys M, Campillo-Artero C, Agodi A, Barchitta M, Gikas A, Palos C, López-Casasnovas G (2020). PLoS One 15(1):e0227139. Crossref |
||||
Shabaan AE, Nour I, Eldegla HE, Nasef N, Shouman B, Abdel-Hady H (2017). Conventional versus prolonged infusion of meropenem in neonates with gram-negative late-onset sepsis. Pediatric Infectious Disease 36(4):358-363. Crossref |
||||
Shah S, Barton G, Fischer A (2015). Pharmacokinetic considerations and dosing strategies of antibiotics in the critically ill patient. Journal of the Intensive Care Society 16(2):147-153. Crossref |
||||
Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, Hotchkiss RS, Levy MM, Marshall JC, Martin GS, Opal SM, Rubenfeld GD, van der Poll T, Vincent JL, Angus DC (2016). The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 315(8):801-810. Crossref |
||||
Taccone FS, Hites M, Beumier M, Scolletta S, Jacobs F (2011). Appropriate antibiotic dosage levels in the treatment of severe sepsis and septic shock. Current Infectious Disease 13(5):406-415. Crossref |
||||
Thabit AK, Hobbs ALV, Guzman OE, Shea KM (2019). The pharmacodynamics of prolonged infusion β-lactams for the treatment of pseudomonas aeruginosa infections: a systematic review. Clinical Therapeutics 41(11):2397-2415.e8. Crossref |
||||
Vardakas KZ, Voulgaris GL, Maliaros A, Samonis G, Falagas ME (2018). Prolonged versus short-term intravenous infusion of antipseudomonal β-lactams for patients with sepsis: a systematic review and meta-analysis of randomised trials. Lancet Infectious Diseases 18(1):108-120. Crossref |
||||
Varghese JM, Roberts JA, Lipman J (2011). Antimicrobial pharmacokinetic and pharmacodynamic issues in the critically ill with severe sepsis and septic shock. Critical Care Clinics 27(1):19-34. Crossref |
||||
Vogelman B, Gudmundsson S, Leggett J, Turnidge J, Ebert S, Craig WA (1988). Correlation of antimicrobial pharmacokinetic parameters with therapeutic ef?cacy in an animal model. Journal of Infectious Diseases 158(4):831-847. Crossref |
||||
Wiskirchen DE, Housman ST, Quintiliani R, Nicolau DP, Kuti JL (2013). Comparative pharmacokinetics, pharmacodynamics, and tolerability of ertapenem 1 gram/day administered as a rapid 5-minute infusion versus the standard 30-minute infusion in healthy adult volunteers. Pharmacotherapy 33(3):266-274. Crossref |
||||
Wittau M, Paschke S, Kurlbaum M, Scheele J, Ly NS, Hemper E, Kornmann M, Henne-Bruns D, Bulitta JB (2017). Population pharmacokinetics and target attainment of ertapenem in plasma and tissue assessed via microdialysis in morbidly obese patients after laparoscopic visceral surgery. Antimicrobial Agents and Chemotherapy 61(1):e00952-16. Crossref |
||||
Yu Z, Pang X, Wu X, Shan C, Jiang S (2018). Clinical outcomes of prolonged infusion (extended infusion or continuous infusion) versus intermittent bolus of meropenem in severe infection: a meta-analysis. PLoS One 13(7):e0201667. Crossref |
||||
Zeitlinger MA, Derendorf H, Mouton JW, Cars O, Craig WA, Andes D, Theuretzbacher U (2011). Protein binding: do we ever learn?. Antimicrobial Agents and Chemotherapy 55(7):3067-3074. Crossref |
||||
Zhanel GG, Johanson C, Embil JM, Noreddin A, Gin A, Vercaigne L, Hoban DJ (2005). Ertapenem: review of a new carbapenem. Expert Review of Anti-infective Therapy 3(1):23-39. Crossref |
||||
Zhou J, Sulaiman Z, Llorin RM, Hee KH, Lee LSU, Lye DC, Fisher DA, Tam VH (2014). Pharmacokinetics of ertapenem in outpatients with complicated urinary tract infections. Journal of Antimicrobial Chemotherapy 69(9):2517-2521. Crossref |
||||
Zusman O, Farbman L, Tredler Z, Daitch V, Lador A, Leibovici L, Paul M (2015). Association between hypoalbuminemia and mortality among subjects treated with ertapenem versus other carbapenems: prospective cohort study. Clinical Microbiology and Infection 21(1):54-58. Crossref |
||||
Zuur MA, Ghimire S, Bolhuis MS, Wessels AMA, van Altena R, de Lange WCM, Kosterink JGW, Touw DJ, van der Werf TS, Akkerman OW, Alffenaar JWC (2018). Pharmacokinetics of 2,000 milligram ertapenem in tuberculosis patients. Antimicrobial Agents and Chemotherapy 62(5):e02250-17. Crossref |
Copyright © 2025 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0